Literature DB >> 17171454

Fructo-oligosaccharide reduces inflammation in a dextran sodium sulphate mouse model of colitis.

Jessica Winkler1, Ross Butler, Erin Symonds.   

Abstract

Fructo-oligosaccharide (FOS) is a prebiotic that stimulates the colonic growth of bifidobacteria to promote intestinal health. This study assessed whether FOS can reduce intestinal damage associated with ulcerative colitis and accelerate recovery in a mouse model. C57BL/6 mice received 2% dextran sulphate sodium for 7 days (days 8-14). FOS (1.5 g/mL) treatment was administered twice daily (n=10/group): before and during colitis (days 1-14); during colitis (days 10-14); and during colitis and the recovery period (days 10-19). Disease activity was scored daily and colonic damage was assessed by histological analysis. FOS treatment significantly reduced disease activity and damage in the distal colon (P < .05). Treatment with FOS (days 10-14) had increased crypt depth (116+/-6 microm) compared to water treatment (90+/-4 microm, P < .05). FOS treatment (days 10-19) produced a faster recovery from damage with increased crypt depth and crypt area. These results demonstrate the protective effect of FOS treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17171454     DOI: 10.1007/s10620-006-9224-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  36 in total

Review 1.  Prebiotic effects of inulin and oligofructose.

Authors:  S Kolida; K Tuohy; G R Gibson
Journal:  Br J Nutr       Date:  2002-05       Impact factor: 3.718

2.  Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats.

Authors:  J M Campbell; G C Fahey; B W Wolf
Journal:  J Nutr       Date:  1997-01       Impact factor: 4.798

3.  Five-week intake of short-chain fructo-oligosaccharides increases intestinal absorption and status of magnesium in postmenopausal women.

Authors:  M Tahiri; J C Tressol; J Arnaud; F Bornet; C Bouteloup-Demange; C Feillet-Coudray; V Ducros; D Pépin; F Brouns; A M Rayssiguier; C Coudray
Journal:  J Bone Miner Res       Date:  2001-11       Impact factor: 6.741

4.  Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects.

Authors:  E Gaudio; G Taddei; A Vetuschi; R Sferra; G Frieri; G Ricciardi; R Caprilli
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

Review 5.  Ulcerative colitis.

Authors:  Richard J Farrell; Mark A Peppercorn
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

6.  Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats.

Authors:  György Rumi; Ryouichi Tsubouchi; Mitsuaki Okayama; Shinichi Kato; Gyula Mózsik; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

7.  Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin.

Authors:  G R Gibson; E R Beatty; X Wang; J H Cummings
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

8.  Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis.

Authors:  Thorsten Vowinkel; Theodore J Kalogeris; Mikiji Mori; Christian F Krieglstein; D Neil Granger
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

9.  Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine.

Authors:  L G Axelsson; E Landström; A C Bylund-Fellenius
Journal:  Aliment Pharmacol Ther       Date:  1998-09       Impact factor: 8.171

10.  Regulatory effects of bifidobacteria on the growth of other colonic bacteria.

Authors:  G R Gibson; X Wang
Journal:  J Appl Bacteriol       Date:  1994-10
View more
  14 in total

Review 1.  Role of the gut microbiota in defining human health.

Authors:  Kei E Fujimura; Nicole A Slusher; Michael D Cabana; Susan V Lynch
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

2.  Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice.

Authors:  Fermín Capitán-Cañadas; Borja Ocón; Carlos José Aranda; Andrea Anzola; María Dolores Suárez; Antonio Zarzuelo; Fermín Sánchez de Medina; Olga Martínez-Augustin
Journal:  Eur J Nutr       Date:  2015-07-08       Impact factor: 5.614

3.  Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice.

Authors:  Zhuqing Dai; Simin Feng; Anna Liu; Hong Wang; Xiaoxiong Zeng; Chung S Yang
Journal:  Food Res Int       Date:  2018-04-24       Impact factor: 6.475

4.  Prebiotic Supplementation Following Ileocecal Resection in a Murine Model is Associated With a Loss of Microbial Diversity and Increased Inflammation.

Authors:  Michael Laffin; Troy Perry; Heekuk Park; Naomi Hotte; Richard N Fedorak; Aducio Thiesen; Bryan Dicken; Karen L Madsen
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

Review 5.  Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome.

Authors:  Larissa S Celiberto; Franziska A Graef; Genelle R Healey; Else S Bosman; Kevan Jacobson; Laura M Sly; Bruce A Vallance
Journal:  Immunology       Date:  2018-05-16       Impact factor: 7.397

Review 6.  Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.

Authors:  Jessica Soldavini; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2013-07-10       Impact factor: 3.199

Review 7.  The interplay between fiber and the intestinal microbiome in the inflammatory response.

Authors:  Shiu-Ming Kuo
Journal:  Adv Nutr       Date:  2013-01-01       Impact factor: 8.701

Review 8.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

Review 9.  Prebiotics in chronic intestinal inflammation.

Authors:  Mirjam A C Looijer-van Langen; Levinus A Dieleman
Journal:  Inflamm Bowel Dis       Date:  2009-03       Impact factor: 5.325

10.  Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases.

Authors:  D Ortuño Sahagún; A L Márquez-Aguirre; S Quintero-Fabián; R I López-Roa; A E Rojas-Mayorquín
Journal:  PPAR Res       Date:  2012-11-28       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.